CAR-T Therapy for Lymphoma: Barriers and Solutions to Access
CAR-T therapy is a new and exciting treatment option for lymphoma, but there are several barriers that prevent patients from accessing this treatment. Join Dr. Marc Hoffmann, lymphoma specialist, to learn about these barriers and how to overcome them.
Hannah introduces the agenda and our featured speaker Marc Hoffmann, MD
Dr. Hoffmann talks about CAR-T therapy
Come with your questions and we will answer them!
Marc Hoffmann, MD
Dr. Marc Hoffmann is a board-certified hematologist and oncologist. He is the Director of the Lymphoma Program and Medical Director of Lean and Quality Improvement at The University of Kansas Cancer Center. Dr. Hoffmann served as a Peace Corps volunteer in West Africa, then attended the University of Pennsylvania for medical school and residency, and completed a hematology and oncology fellowship at MD Anderson Cancer Center. Dr. Hoffmann is passionate about the development of novel therapies for CLL and lymphoma, and serves as the principal investigator on multiple clinical trials.
Hannah Loosle
Hannah joined HealthTree Foundation as the Lymphoma Education Manager in 2024. She is a Certified Health Education Specialist and is passionate about helping patients feel empowered through education and connection. Before joining HealthTree, Hannah worked in healthcare policy helping patients advocate for better care, research, and funding. Hannah enjoys baking and going to concerts in her free time.